**INTRODUCTION**

- Patients with multiple sclerosis (MS) report impaired health-related quality of life (HRQoL) compared with the general population. 1

- Declines in HRQoL are apparent in patients early in the course of MS. 2

- More severe disability, relapse activity, and brain magnetic resonance imaging (MRI) disease burden have been associated with worse HRQoL in patients. 3

- Disease-modifying therapies (DMTs) for MS reduce relapses and brain MRI lesion activity and slow disability progression; some DMTs (e.g., natalizumab and ocrelizumab) improve HRQoL. 4

- SELECT was a randomized, double-blind, placebo-controlled trial conducted to evaluate the safety and efficacy of Daclizumab HYP (Daclizumab): an anti-CD25 monoclonal antibody that is in clinical development for the treatment of MS. 5

- Daclizumab was developed to address the potential for inadequacy of the interleukin-2 receptor alpha subunit (IL-2Rα), an immunosuppressant that has been hypothesized to target T-cell activation through both direct antagonism of CD25 and indirect inhibition of the transcription factor STAT5, leading to a reduction in T-cell activity. 6

**OBJECTIVE**

- Evaluate the efficacy of Daclizumab HYP in MS, in combination with other treatments. 7

**METHODS**

- **Study Design**:
  - SELECT was a 52-week, randomized, double-blind, placebo-controlled study of Daclizumab HYP 150 mg or 300 mg SC at week 0 and week 24 in patients with RRMS. 1
  - The primary end point of SELECT was the annualized relapse rate (ARR) at 52 weeks. 1
  - SELECT included patients using the Nine MS-Specific Impact Scale (NMSIS-9): the Short Form Health Survey (SF-36), the Edwards MS-BDI (EM-BDI). 8

**Figure 1: SELECT Study Design**

- **Assessments**:
  - HRQoL instruments used in SELECT and the direction of improvement for each measure are shown in Figure 2.

- **Safety**:
  - The efficacy is different in change from baseline to Weeks 12, 24, and 52 between each Daclizumab HYP dose group and placebo are derived from analysis of covariance, controlling for baseline scores.

- **ED-50 Summary Health Index was computed using the MPH-AI Tart**

- **DISCUSSIONS**
  - In the Daclizumab HYP 300 mg group, significant trends for relapse reduction were observed in SP and ED-50 scores versus placebo at the course of the study.

**REFERENCES**

1. Medikin, Krzysztof, et al. “Daclizumab HYP Improves Quality of Life in Multiple Sclerosis Patients.” Medical University of Lodz, Lodz, Poland. Charles University in Prague, Prague, Czech Republic. St. Josef Hospital/Ruhu University Bochum, Bochum, Germany. Abbot Biometrics, Redwood City, CA, USA. Biogen IDEC, Cambridge, MA, USA.

2. Medikin, Krzysztof, et al. “Daclizumab HYP Improves Quality of Life in Multiple Sclerosis Patients.” Medical University of Lodz, Lodz, Poland. Charles University in Prague, Prague, Czech Republic. St. Josef Hospital/Ruhu University Bochum, Bochum, Germany. Abbot Biometrics, Redwood City, CA, USA. Biogen IDEC, Cambridge, MA, USA.